Stock Detail
ARRAY BIOPHARMA INC
Sector: Biotechnology
Latest Quote @ Mon May 5 10:38:35 (15 min delayed)
| $5.70 |
$5.71 |
$5.72 |
-0.17 |
-2.89% |
|
Last Day's Data
| $5.89 |
$5.91 |
$0.20 |
3.51% |
0.00 |
$5.69 |
| $5.76 |
$5.73 |
912,437.00 |
687.81M |
947,400.00 |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 6.02 |
5.95 |
5.84 |
5.77 |
5.66 |
Stock Profile
Array BioPharma, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs to treat debilitating and life-threatening diseases. The company's drug development pipeline primarily focuses on the treatment of cancer and inflammatory disease, and includes drugs that regulate targets in therapeutically important disease pathways. It offers ARRY-142886 (AZD6244)/MEK, which is in the Phase Ib clinical development, for the treatment of cancer. The company also provides ARRY-334543, ErbB-2/EGFR Inhibitors, and ErbB-2 Inhibitors that are in preclinical models of human cancer. It has collaborations with Amgen; AstraZeneca; Elan; Eli Lilly and Company; Genentech, Inc.; Hoffman-La Roche, Inc.; ICOS Corporation; InterMune, Inc.; Japan Tobacco, Inc.; Procter & Gamble Pharmaceuticals; QLT, Inc.; Ono Pharmaceutical Co., Ltd.; and Takeda Pharmaceutical Company, Ltd. Array was founded in 1998 and is headquartered in Boulder, Colorado.
